ESC 365 - Real-world health status changes with mavacamten in symptomatic obstructive hypertrophic cardiomyopathy (oHCM)

Back

ESC2025 Premium Access

Real-world health status changes with mavacamten in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) - Early findings from COMPASS-HCM

Session: Cardiotoxicity and protection: from bench to bedside

Topic: Cardiovascular Pharmacotherapy

Speaker: Professor A. Wang (Durham, US)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Professor Andrew Wang

Duke University Medical Center, Durham (United States of America)

0 follower

6 more presentations in this session

A UK multicentre experience of osimertinib related cardiovascular toxicity: real world patterns, risk stratification and surveillance

Speaker: Doctor C. Simela (London, GB)

Impact of dapagliflozin on cardiac remodeling and sirtuin expression in rats with type 1 diabetes mellitus

Speaker: Associate Professor M. Okoshi (Botucatu, BR) Mrs A. Marreiros (Botucatu, BR)

Maternal fluconazole use during the third trimester and risk of QT prolongation in the offspring

Speaker: Doctor G. Ninh (Herlev, DK)

Ranolazine ameliorates palmitic acid-induced insulin resistance in HL-1 cardiomyocytes by Ca2+/ CaMKII modulation: an in vitro investigation and population-based cohort study

Speaker: Professor P. Liu (Tainan, TW)

Safety and efficacy of migalastat in Fabry's disease treatment with cardiac impact : a systematic review and meta-analysis

Speaker: Mr L. Oldra (Sao Paulo, BR)

Access the full session

Cardiotoxicity and protection: from bench to bedside

Speakers: Professor A. Wang, Doctor C. Simela, Associate Professor M. Okoshi, Mrs A. Marreiros, Doctor G. Ninh...

Access

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources